Federal Register / Vol. 87, No. 32 / Wednesday, February 16, 2022 / Notices 8851 

2022, for Topic I, the committee will 

meet in open session to hear an 

overview of the research programs in 

the Gene Transfer and Immunogencity 

Branch, Division of Cellular and Gene 

Therapies, Office of Tissues and 

Advanced Therapies, Center for 

Biologics Research. After the Topic I 

open session, the meeting will be closed 

to the public for committee 

deliberations. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its website prior to the 

meeting, the background material will 

be made publicly available on FDA’s 

website at the time of the advisory 

committee meeting. Background 

material and the link to the online 

teleconference meeting room will be 

available at https://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee meeting 

link. The meeting will include slide 

presentations with audio components to 

allow the presentation of materials in a 

manner that most closely resembles an 

in-person advisory committee meeting. 

Procedure: On March 10, 2022, from 

10 a.m. to 12:40 p.m. Eastern Time, the 

meeting is open to the public for Topic 

I. Interested persons may present data, 

information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before 

March 3, 2022. Oral presentations from 

the public will be scheduled between 

approximately 11:40 a.m. and 12:40 

p.m. Eastern Time. Those individuals 

interested in making formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before February 

23, 2022. Time allotted for each 

presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by February 24, 2022. 

Closed Committee Deliberations: On 

March 10, 2022, from 12:40 p.m. to 1:30 

p.m. Eastern Time for Topic I, the 

meeting will be closed to permit 

discussion where disclosure would 

constitute a clearly unwarranted 

invasion of personal privacy (5 U.S.C. 

552b(c)(6)). The recommendations of the 

advisory committee regarding the 

progress of the individual investigators’ 

research programs, along with other 

information, will be discussed during 

this session. We believe that public 

discussion of these recommendations on 

individual scientists would constitute 

an unwarranted invasion of personal 

privacy. 

For press inquiries, please contact the 

Office of Media Affairs at fdaoma@

fda.hhs.gov or 301–796–4540. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with disabilities. 

If you require accommodations due to a 

disability, please contact Christina Vert 

at ctgtac@fda.hhs.gov (see FOR FURTHER

INFORMATION CONTACT) at least 7 days in 

advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our website at 

https://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: February 10, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–03366 Filed 2–15–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Presidential Advisory 

Council on HIV/AIDS 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice of a virtual meeting. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Service is hereby giving notice that the 

Presidential Advisory Council on HIV/ 

AIDS (PACHA or the Council) will be 

holding the 73rd full Council meeting 

utilizing virtual technology on Monday, 

March 14 and Tuesday, March 15, 2022 

from approximately 10:00–4:30 p.m. 

(ET) on both days. The meeting will be 

open to the public and there will be an 

interactive community engagement 

session during the first day of the 

meeting. Additionally, there will be a 

public comment session during the 

meeting; pre-registration is required to 

provide public comment. To pre-register 

to provide public comment, please send 

an email to PACHA@hhs.gov and 

include your name, organization, and 

title by close of business Monday, 

March 7, 2022. If you decide you would 

like to provide public comment but do 

not pre-register, you may submit your 

written statement by emailing PACHA@

hhs.gov by close of business Tuesday, 

March, 22, 2022. The meeting agenda 

will be posted on the PACHA page on 

HIV.gov at https://www.hiv.gov/federalresponse/pacha/about-pacha prior to 

the meeting. 

DATES: The meeting will be held on 

Monday, March 14 and Tuesday March 

15, 2022 from approximately 10:00–4:30 

p.m. (ET) on both days. This meeting 

will be conducted utilizing virtual 

technology. 

ADDRESSES: Instructions on attending 

this meeting virtually will be posted 

prior to the meeting at: https://

www.hiv.gov/federal-response/pacha/ 

about-pacha. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Caroline Talev, MPA, Management 

Analyst, Presidential Advisory Council 

on HIV/AIDS, 330 C Street SW, Room 

L609A, Washington, DC 20024; (202) 

795–7622 or PACHA@hhs.gov. 

Additional information can be obtained 

by accessing the Council’s page on the 

HIV.gov site at www.hiv.gov/pacha. 

SUPPLEMENTARY INFORMATION: PACHA 

was established by Executive Order 

12963, dated June 14, 1995, as amended 

by Executive Order 13009, dated June 

14, 1996 and is currently operating 

under the authority given in Executive 

Order 14048, dated September 30, 2021. 

The Council was established to provide 

advice, information, and 

recommendations to the Secretary 

regarding programs and policies 

intended to promote effective HIV 

diagnosis, treatment, prevention, and 

quality care services. The functions of 

the Council are solely advisory in 

nature. 

The Council consists of not more than 

35 members. Council members are 

selected from prominent community 

leaders with particular expertise in, or 

knowledge of, matters concerning HIV 

and AIDS, public health, global health, 

population health, philanthropy, 

marketing or business, as well as other 

national leaders held in high esteem 

from other sectors of society. PACHA 

selections also include persons with 

lived HIV experience and racial/ethnic 

and sexual and gender minority persons 

disproportionately affected by HIV. 


jspears on DSK121TN23PROD with NOTICES1
8852 Federal Register / Vol. 87, No. 32 / Wednesday, February 16, 2022 / Notices 

Council members are appointed by the 

Secretary. 

Dated: January 31, 2022. 

B. Kaye Hayes, 

Acting Director, Office of Infectious Disease 

and HIV/AIDS Policy, Executive Director, 

Presidential Advisory Council on HIV/AIDS, 

Office of the Assistant Secretary for Health, 

Department of Health and Human Services. 

[FR Doc. 2022–03353 Filed 2–15–22; 8:45 am] 

BILLING CODE 4150–43–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

60-Day Report to Congress on 

Domestic Content Procurement 

Preferences Applicable to Federal 

Financial Assistance 

AGENCY: Assistant Secretary for 

Financial Resources (ASFR), Health and 

Human Services (HHS or the 

Department). 

ACTION: Notice. 

SUMMARY: The Infrastructure Investment 

and Jobs Act (IIJA) requires Federal 

awarding agencies to identify and report 

to Congress each Federal financial 

assistance program for infrastructure 

administered by the Federal awarding 

agency. 

FOR FURTHER INFORMATION CONTACT: 

Johanna Nestor at Johanna.Nestor@

hhs.gov or (202) 631–0420. 

SUPPLEMENTARY INFORMATION: Section 

70913(b) of the IIJA requires that the 

report: 

• Identify all domestic content 

procurement preferences applicable to 

the Federal financial assistance; 

• Assess the applicability of the 

domestic content procurement 

preference requirements, including—(A) 

section 313 of title 23, United States 

Code; (B) section 5323(j) of title 49, 

United States Code; (C) section 22905(a) 

of title 49, United States Code; (D) 

section 50101 of title 49, United States 

Code; (E) section 603 of the Federal 

Water Pollution Control Act (33 U.S.C. 

1388); (F) section 1452(a)(4) of the Safe 

Drinking Water Act (42 U.S.C. 300j– 

12(a)(4)); (G) section 5035 of the Water 

Infrastructure Finance and Innovation 

Act of 2014 (33 U.S.C. 3914); (H) any 

domestic content procurement 

preference included in an 

appropriations Act; and (I) any other 

domestic content procurement 

preference in Federal law (including 

regulations); 

• Provide details on any applicable 

domestic content procurement 

preference requirement, including the 

purpose, scope, applicability, and any 

exceptions and waivers issued under 

the requirement; and, 

• Include a description of the type of 

infrastructure projects that receive 

funding under the program, including 

information relating to— 

Æ the number of entities that are 

participating in the program; 

Æ the amount of Federal funds that 

are made available for the program for 

each fiscal year; and, 

Æ any other information the head of 

the Federal agency determines to be 

relevant. 

In accordance with the Office of 

Management and Budget (OMB) 

Memorandum M–22–08— 

‘‘Identification of Federal Financial 

Assistance Infrastructure Programs 

Subject to the Build America, Buy 

America Provisions of the Infrastructure 

Investment and Jobs Act,’’ Federal 

awarding agencies must also include a 

separate notice to each appropriate 

congressional committee, including the 

Committee on Homeland Security and 

Governmental Affairs, the Committee on 

Commerce, Science, and Transportation, 

the Committee on Environment and 

Public Works, the Committee on 

Banking, Housing, and Urban Affairs, 

and the Committee on Armed Services 

of the Senate; and the Committee on 

Oversight and Reform, the Committee 

on Armed Services, and the Committee 

on Transportation and Infrastructure of 

the House of Representatives. 

The following report provides the 

Department of Health and Human 

Services (HHS) initial analysis of its 

programs and the Build America, Buy 

America requirements. 

Background: Title IX of the IIJA, 

entitled ‘‘Build America, Buy America’’ 

(BABA), requires that no later than May 

14, 2022, each Federal awarding agency 

must ensure that none of the funds 

made available for a Federal financial 

assistance program for infrastructure 

may be obligated for a project, unless all 

of the iron, steel, manufactured 

products, and construction materials 

used in the project, are produced in the 

United States (absent a waiver 

authorized by statute). Section 70912(5) 

of the IIJA, defines ‘‘infrastructure’’ to 

include at a minimum, the structures, 

facilities, and equipment for, in the 

United States—roads, highways, and 

bridges; public transportation; dams, 

ports, harbors, and other maritime 

facilities; intercity passenger and freight 

railroads; freight and intermodal 

facilities; airports; water systems, 

including drinking water and wastewater systems; electrical transmission 

facilities and systems; utilities; 

broadband infrastructure; and buildings 

and real property. 

Analysis: The financial assistance 

programs funded by HHS focus on 

medical research, health services, and 

essential human services. As part of this 

focus, HHS occasionally provides 

construction support for health centers, 

medical centers, and research facilities. 

The IIJA, through the BABA imposes 

requirements on Federal financial 

assistance for infrastructure projects, 

and focuses on sectors of domestic 

infrastructure beyond the scope of 

HHS’s programs. HHS has determined 

that such construction support is not 

subject to BABA requirements. If it is 

determined on a case-by-case basis that 

the BABA requirements apply to any 

particular Federal financial assistance 

provided by HHS, HHS will evaluate 

whether pursuing a waiver authorized 

by statute is appropriate. 

Historically, most recently in May 

2019, OMB has concurred with HHS’s 

characterization of HHS financial 

assistance programs. On December 20, 

2021, OMB issued to Federal awarding 

agencies, Memorandum M–22–08— 

‘‘Identification of Federal Financial 

Assistance Infrastructure Programs 

Subject to the Build America, Buy 

America Provisions of the Infrastructure 

Investment and Jobs Act.’’ The 

Memorandum provides additional 

implementation instructions, however, 

the Memorandum did not alter HHS’s 

current assessment. Should OMB issue 

additional guidance, HHS will reevaluate the applicability of the BABA 

requirements to our financial assistance 

programs. 

Alice Bettencourt, 

Deputy Assistant Secretary for Grants. 

[FR Doc. 2022–03363 Filed 2–15–22; 8:45 am] 

BILLING CODE 4150–24–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Secretary’s Advisory 

Committee on Human Research 

Protections 

AGENCY: Department of Health and 

Human Services, Office of the Secretary, 

Office of the Assistant Secretary for 

Health. 

ACTION: Notice. 

SUMMARY: Pursuant to Section 10(a) of 

the Federal Advisory Committee Act 

notice is hereby given that the 

Secretary’s Advisory Committee on 

Human Research Protections (SACHRP) 

will hold a meeting that will be open to 

the public. Information about SACHRP, 

the full meeting agenda, and 

instructions for linking to public access 

will be posted on the SACHRP website 


jspears on DSK121TN23PROD with NOTICES1